Smith+Nephew has inked a distribution agreement with SI Bone for the iFuse TORQ portfolio.
The portfolio includes two implants with indications for pelvic fracture fixation and fusion of the SI joint, according to a Feb. 23 news release from Smith+Nephew.
The iFuse TORQ TNT has received the FDA’s breakthrough device designation and is eligible for a Medicare New Technology Add-on Payment.
The partnership expands access to differentiated products, deepens surgeon engagement and drives growth, according to Scott Gunn, vice president trauma, extremities and shoulder at Smith+Nephew.
